Pharmaceuticals
Pharmaceutical manufacturers and their lobbying arm PhRMA. Active on drug pricing, FDA approval, Medicare Part D.
Tracked PAC receipts
$387,848
Tracked PAC giving
$2,807,000
Independent expenditures
$0
LDA lobbying spend
$88,548,938
How money flowed in this sector
IDonors put $388K into 10 sector PACs tracked here, led by ELI LILLY & COMPANY PAC, ELI LILLY AND COMPANY POLITICAL ACTION COMMITTEE, SANOFI US SERVICES INC. EMPLOYEES' POLITICAL ACTION COMMITTEE.
IIThose PACs spent $3M supporting candidates and on independent expenditures, with the top tracked recipients being DSCC, GUTHRIE FOR CONGRESS, NATIONAL REPUBLICAN CONGRESSIONAL COMMITTEE-LEGAL FUND.
IIISector PACs and clients took documented positions on 10 policy outcomes, including Pharmacy Benefit Manager Reform Act; MARCH-IN Rights Proposal (NIH Framework); Insulin Price Caps - State-Level Legislation.
Network graph
Top sector PACs (by tracked giving)
Top donors to sector PACs
| # | Name | Tracked $ |
|---|---|---|
| 1 | JONSSON, PATRIKperson | $7K |
| 2 | DE FELIPPIS, MICHAEL R DR PH.D.person | $7K |
| 3 | HEINE, ROBERTperson | $7K |
| 4 | LIN, LINUS Sperson | $7K |
| 5 | OLEKSIW, JENNIFER L MRSperson | $7K |
| 6 | O'NEAIL, SHAWNperson | $7K |
| 7 | CROANING, JAMES P MRperson | $7K |
| 8 | YUFFA, ILYAperson | $6K |
| 9 | VAN SANT HOFFMAN, ELIZABETH ANNperson | $6K |
| 10 | GILROY, JAMES C IIIperson | $6K |
Top recipients of sector PAC spending
| # | Name | Tracked $ |
|---|---|---|
| 1 | DSCCpac | $210K |
| 2 | GUTHRIE FOR CONGRESSpac | $67K |
| 3 | NATIONAL REPUBLICAN CONGRESSIONAL COMMITTEE-LEGAL FUNDpac | $60K |
| 4 | SCOTT PETERS FOR CONGRESSpac | $59K |
| 5 | SCALISE FOR CONGRESSpac | $51K |
| 6 | GROW THE MAJORITYpac | $50K |
| 7 | CMTE. FOR HISPANIC CAUSES/BUILDING OUR LEADERSHIP DIVERSITY PAC (BOLD PAC)pac | $50K |
| 8 | SCALISE LEADERSHIP FUNDpac | $49K |
| 9 | DEMOCRATIC CONGRESSIONAL CAMPAIGN COMM. - BLDG FUNDpac | $45K |
| 10 | KEVIN MCCARTHY FOR CONGRESSpac | $41K |
Policy outcomes the sector touched
| # | Outcome | Positions |
|---|---|---|
| 1 | Pharmacy Benefit Manager Reform Act legislation · introduced | 27 |
| 2 | MARCH-IN Rights Proposal (NIH Framework) regulation · proposed · proposed | 18 |
| 3 | Insulin Price Caps - State-Level Legislation legislation · enacted | 14 |
| 4 | Prior Authorization Reform (Improving Seniors Timely Access to Care Act) legislation · introduced | 9 |
| 5 | Inflation Reduction Act - Energy Provisions (H.R.5376) legislation · enacted | 8 |
| 6 | Sugar Reform Act (S.832, 118th Congress) legislation · failed | 7 |
| 7 | Inflation Reduction Act - Drug Pricing Provisions (H.R.5376) legislation · enacted | 6 |
| 8 | Medicare Program; Hospital Inpatient Prospective Payment Systems for Acute Care regulation · introduced | 6 |
| 9 | Medicare and Medicaid Programs: Hospital Outpatient Prospective Payment and Ambu regulation · introduced · amended | 6 |
| 10 | Health Data, Technology, and Interoperability: Patient Engagement, Information S regulation · introduced | 6 |
Methodology
Industry-level totals are computed by summing donations and lobbying filings where the donor, recipient, or client is tagged with the pharmaceuticals sector. Numbers reflect QPQ-tracked totals only and may understate the official FEC cycle totals where the inflow ingest is incomplete. Click any entity to see its full profile with the breakdown of tracked vs FEC cycle totals.